The discoveries of cancer research have been translated into the clinical management of
lung cancer patients. So far, the approach of targeted therapy that is directed towards certain …

Brain metastases are very common in lung cancer patients. The condition of these patients
is complicated and difficult to treat, and adverse reactions following treatment can affect the …

Lung cancer is the leading cause of cancer-related mortality worldwide. The discovery of
tyrosine kinase inhibitors effectively targeting EGFR mutations in lung cancer patients in …

Following the results of the CROWN phase III trial, the third-generation macrocyclic ALK
inhibitor lorlatinib has been introduced as a salvage option after the failure of a first-line TKI …

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, and adjuvant
targeted therapy has shown great benefits for the NSCLC patients with specific genomic …

Gene fusions occur in up to 17% of solid tumours. Oncogenic kinases are often involved in
such fusions. In lung cancer, almost 30% of patients carrying an activated oncogene show …

Background This study aimed to describe the incidence, clinical characteristics, and
prognosis of lung cancer patients with synchronous bone metastasis (SBM) and to analyze …

Zusammenfassung In der Diagnostik des Lungenkarzinoms nimmt die Histopathologie
traditionell eine prominente Rolle ein. Diese hat in der letzten Zeit mit der Einführung …

Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related death in both
men and women. The ability of cancer cells to break-off from the primary tumor and spread …

Up to 70% of non-small cell lung cancer (NSCLC) patients develop central nervous system
(CNS) metastases during the course of their disease, especially those with oncogenic …